Navocaftor by Sionna Therapeutics for Cystic Fibrosis: Likelihood of Approval

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

How immune cells shape our earliest breaths

Study profiles the development of immune cells in human lungs during embryonic and fetal stages, revealing their influence on epithelial cell fate and lung development.

January 1, 2024

Computational framework protects privacy in voice-based cognitive health assessments

Digital voice recordings contain valuable information that can indicate an individual’s cognitive health, offering a non-invasive and efficient method for assessment.

March 14, 2025

Hearing aids may slow mental decline in those at higher risk of dementia, study finds

Doctors have long suspected that hearing loss in older adults hastens dementia, the cognitive decline associated with aging. A new study published in The Lancet

July 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.